Researchers sought to determine if reducing the starting dose of TKI therapy in patients with metastatic RCC would improve tolerability without reducing efficacy.
Investigators report a cumulative 10-year incidence of end-stage kidney disease of 2.5% among patients who undergo surgery for renal cell carcinoma (RCC), which is 10 times higher than in patients without RCC.
Investigators report findings from the largest analysis characterizing objective imaging response among patients with mRCC treated in routine clinical practice.
